Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2003
Cognitive fatigue during a test requiring sustained attention: a pilot studySteven R Schwid, Carolyn M Tyler, Eileen A Scheid, et al.Journal of Rehabilitation Research and Development|October 19, 2007
Comparison of mobility device delivery within Department of Veterans Affairs for individuals with multiple sclerosis versus spinal cord injuryFabrisia Ambrosio, Michael L Boninger, Shirley G Fitzgerald, et al.Journal of the Neurological Sciences|April 29, 2014
Hand dexterity and direct disease related cost in multiple sclerosisMarcus W Koch, T Jock Murray, John Fisk, et al.Movement Disorders : Official Journal of the Movement Disorder Society|November 13, 2009
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohortsConnie Marras, Anthony E Lang, Shirley W Eberly, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 21, 2006
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida, Steven R Schwid, William B White, et al.Muscle & Nerve|September 1, 2010
Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann, Alec B O'Connor, Steven R Schwid, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, et al.The Lancet. Neurology|September 16, 2008
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D Mikol, Frederik Barkhof, Peter Chang, et al.Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.Pageof 4